Clinical trial in Fragile X syndrome – 4 Australian sites

April 26th, 2023

The RECONNECT clinical trial is underway in Adelaide, Brisbane, Melbourne and Sydney, together with sites in the UK and in the US.  Participants aged 3-22 years old who have a confirmed diagnosis of Fragile X syndrome may be eligible to enrol in the trial.

The RECONNECT study is evaluating the effectiveness of Zygel, an investigational treatment produced by Zynerba Pharmaceuticals for some behavioural symptoms of Fragile X syndrome.

Zygel is a “pharmaceutically-manufactured cannabidiol, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.  Zygel is being developed for patients affected by Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q).”   [Source:  Zynerba website ]

The RECONNECT clinical trial site locations in Australia are:
ADELAIDE – Flinders Medical Centre
BRISBANE – Queensland Children’s Hospital
MELBOURNE – Fragile X Alliance Clinic
SYDNEY – Westmead Children’s Hospital

For more information or to register interest in a child’s participation in the trial see this website:

End of Financial Year donation will make a difference

Your generous donation will help FXAA ensure people living with Fragile X are connected, included, understood and empowered. Specifically, your donation (no matter how big or small) will help us maintain and deliver support and connections to the Fragile X community: 1. Counselling support 2. FXAA Helpline - available 5 days per week 3. Webinar program 4. Peer connection and referrals 5. Advocacy work – for example, our Fragile X Care | Adults & Ageing study that we’re undertaking collaboratively with the Centre for Disability Studies is the first Australian study on the support needs, health & wellbeing of adults with Fragile X Syndrome as they age. All support is sincerely appreciated and helps us make a difference.

Fragile X Logo
Registered Charity Logo